# INCYTE CORPORATION (INCY) FY2026 Q2 P&L / Income Statement - Company: INCYTE CORPORATION (INCY) - Period: 2026-04-01 to 2026-06-30 - Filing: Q2 FY2026 10-Q, filed 2026-07-28, accession number 0000879169-26-000056 - Page: https://plicit.ai/financials/incy/fy2026-q2-income-statement - Chart image: https://plicit.ai/charts/incy-fy2026-q2-income-statement-sankey.png ## Chart details: Revenue by Product and Service by Arrangement Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 1,674,039,000 US dollars - **Cost of sales (including definite-lived intangible amortization)**: 104,957,000 US dollars - **Gross profit (calculated)**: 1,569,082,000 US dollars - **Operating expenses (calculated)**: 871,184,000 US dollars - **Income from operations**: 697,898,000 US dollars - **Other income (expense), net (calculated)**: 53,616,000 US dollars - **Income before provision for income taxes**: 751,514,000 US dollars - **Provision for income taxes**: 165,909,000 US dollars - **Net income**: 585,605,000 US dollars - **ICLUSIG**: 34,394,000 US dollars - **JAKAFI**: 816,659,000 US dollars - **JAKAVI Royalty Revenues**: 124,190,000 US dollars - **MINJUVI/MONJUVI**: 53,686,000 US dollars - **Milestone and contract revenues**: 11,200,000 US dollars - **NIKTIMVO**: 60,309,000 US dollars - **OLUMIANT Royalty Revenues**: 38,479,000 US dollars - **Other**: 5,330,000 US dollars - **PEMAZYRE**: 23,418,000 US dollars - **TABRECTA Royalty Revenues**: 6,691,000 US dollars - **ZYNYZ**: 49,947,000 US dollars - **Product royalty revenues**: 174,690,000 US dollars - **JAKAVI - Novartis**: 124,200,000 US dollars - **OLUMIANT - Eli Lilly**: 38,500,000 US dollars - **TABRECTA - Novartis**: 6,700,000 US dollars - **Undisclosed (calculated)**: 105,646,000 US dollars - **Research and development**: 516,950,000 US dollars - **Selling, general and administrative**: 351,735,000 US dollars - **Asset impairment and related disposal costs**: 0 US dollars - **Loss on change in fair value of acquisition-related contingent consideration**: 2,499,000 US dollars - **Contract dispute settlement**: 0 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Product and Service (12 categories) - Page: https://plicit.ai/financials/incy/fy2026-q2-income-statement/revenue-by-product-and-service-12-categories - Chart image: https://plicit.ai/charts/incy-fy2026-q2-revenue-by-product-and-service-12-categories-sankey.png Income statement for 2026-04-01 through 2026-06-30. View: Product and service (12 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 1,674,039,000 US dollars - **Cost of sales (including definite-lived intangible amortization)**: 104,957,000 US dollars - **Gross profit (calculated)**: 1,569,082,000 US dollars - **Operating expenses (calculated)**: 871,184,000 US dollars - **Income from operations**: 697,898,000 US dollars - **Other income (expense), net (calculated)**: 53,616,000 US dollars - **Income before provision for income taxes**: 751,514,000 US dollars - **Provision for income taxes**: 165,909,000 US dollars - **Net income**: 585,605,000 US dollars - **Milestone and contract revenues**: 11,200,000 US dollars - **JAKAFI**: 816,659,000 US dollars - **OPZELURA**: 449,736,000 US dollars - **ICLUSIG**: 34,394,000 US dollars - **PEMAZYRE**: 23,418,000 US dollars - **MINJUVI/MONJUVI**: 53,686,000 US dollars - **NIKTIMVO**: 60,309,000 US dollars - **ZYNYZ**: 49,947,000 US dollars - **JAKAVI Royalty Revenues**: 124,190,000 US dollars - **OLUMIANT Royalty Revenues**: 38,479,000 US dollars - **TABRECTA Royalty Revenues**: 6,691,000 US dollars - **Other**: 5,330,000 US dollars - **Research and development**: 516,950,000 US dollars - **Selling, general and administrative**: 351,735,000 US dollars - **Asset impairment and related disposal costs**: 0 US dollars - **Loss on change in fair value of acquisition-related contingent consideration**: 2,499,000 US dollars - **Contract dispute settlement**: 0 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Product and Service (3 categories) - Page: https://plicit.ai/financials/incy/fy2026-q2-income-statement/revenue-by-product-and-service-3-categories - Chart image: https://plicit.ai/charts/incy-fy2026-q2-revenue-by-product-and-service-3-categories-sankey.png Income statement for 2026-04-01 through 2026-06-30. View: Product and service (3 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 1,674,039,000 US dollars - **Cost of sales (including definite-lived intangible amortization)**: 104,957,000 US dollars - **Gross profit (calculated)**: 1,569,082,000 US dollars - **Operating expenses (calculated)**: 871,184,000 US dollars - **Income from operations**: 697,898,000 US dollars - **Other income (expense), net (calculated)**: 53,616,000 US dollars - **Income before provision for income taxes**: 751,514,000 US dollars - **Provision for income taxes**: 165,909,000 US dollars - **Net income**: 585,605,000 US dollars - **Net sales**: 1,488,149,000 US dollars - **Product royalty revenues**: 174,690,000 US dollars - **Milestone and contract revenues**: 11,200,000 US dollars - **Research and development**: 516,950,000 US dollars - **Selling, general and administrative**: 351,735,000 US dollars - **Asset impairment and related disposal costs**: 0 US dollars - **Loss on change in fair value of acquisition-related contingent consideration**: 2,499,000 US dollars - **Contract dispute settlement**: 0 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Geography - Page: https://plicit.ai/financials/incy/fy2026-q2-income-statement/revenue-by-geography - Chart image: https://plicit.ai/charts/incy-fy2026-q2-revenue-by-geography-sankey.png Income statement for 2026-04-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 1,674,039,000 US dollars - **Cost of sales (including definite-lived intangible amortization)**: 104,957,000 US dollars - **Gross profit (calculated)**: 1,569,082,000 US dollars - **Operating expenses (calculated)**: 871,184,000 US dollars - **Income from operations**: 697,898,000 US dollars - **Other income (expense), net (calculated)**: 53,616,000 US dollars - **Income before provision for income taxes**: 751,514,000 US dollars - **Provision for income taxes**: 165,909,000 US dollars - **Net income**: 585,605,000 US dollars - **UNITED STATES**: 1,560,110,000 US dollars - **Europe**: 105,131,000 US dollars - **Other countries**: 8,798,000 US dollars - **Research and development**: 516,950,000 US dollars - **Selling, general and administrative**: 351,735,000 US dollars - **Asset impairment and related disposal costs**: 0 US dollars - **Loss on change in fair value of acquisition-related contingent consideration**: 2,499,000 US dollars - **Contract dispute settlement**: 0 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.